(Reuters) – Gilead Sciences Inc (NASDAQ 🙂 posted a 26% increase in quarterly revenue on Thursday, helped by sales of its antiviral drug, remdesivir, which is licensed to treat COVID-19 patients worldwide. . Remdesivir generated $ 1.9 billion in the fourth quarter ending December 31, above analysts’ estimates of $ 1.34 billion, according to Refinitiv IBES data.
Disclaimer: Fusion Media wishes to remind you that the data contained on this website is not necessarily accurate or in real time. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges but by market makers, so prices may not be accurate and may differ from the actual market price, which means that prices are indicative and not appropriate for commercial purposes. Therefore, Fusion Media assumes no responsibility for any business losses you may incur as a result of the use of this data. data, quotes, charts and buy / sell signals contained in this website. Be fully informed about the risks and costs associated with trading financial markets, it is one of the riskiest investment forms possible.